EQ
EQ.US Equillium Inc
- Market cap
- USD 101M
- P/E
- -
- P/B
- 1.84x
- ROE
- -36.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is EQ.US undervalued?
Graham numberThe Graham number of Equillium Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Equillium Inc fundamental analysis
No fundamental analysis for Equillium Inc yet.
Equillium Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Equillium Inc
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases. The company was…
Full company profileEquillium Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Equillium Inc annual financial statements
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 15.8M | 36.1M | 41.1M | 130K | - |
| Gross Profit | -122.00 | -6.10K | -23.0K | -45.0K | -72.0K | 15.8M | 36.1M | 41.1M | -116K | - |
| Operating Income | -1.71M | -8.62M | -26.7M | -29.5M | -37.8M | -62.1M | -14.5M | -8.27M | -23.6M | -21.1M |
| EBITDA | -1.88M | -8.61M | -26.7M | -29.5M | -37.7M | -61.3M | -12.1M | -7.57M | -22.3M | -19.9M |
| Net Income | -2.26M | -13.3M | -25.6M | -29.8M | -39.0M | -62.4M | -13.3M | -8.07M | -22.4M | -19.4M |
| EPS | -0.14 | -1.09 | -1.47 | -1.46 | -1.35 | -1.85 | -0.38 | -0.23 | -0.24 | -0.17 |
| Balance Sheet | ||||||||||
| Total Assets | 7.15M | 67.2M | 55.5M | 85.4M | 85.4M | 78.4M | 50.5M | 25.6M | 31.9M | 55.8M |
| Total Liabilities | 9.40M | 2.23M | 13.7M | 15.6M | 18.9M | 46.5M | 28.0M | 6.54M | 3.29M | 3.13M |
| Shareholders' Equity | -2.25M | 64.9M | 41.8M | 69.9M | 66.5M | 31.9M | 22.6M | 19.1M | 28.6M | 52.7M |
| Cash & Short-term Investments | 7.10M | 65.9M | 53.1M | 82.2M | 80.7M | 71.0M | 40.9M | 22.6M | 30.3M | 53.3M |
| Total Debt | 16.1M | 200K | 9.68M | 9.94M | 10.6M | 10.2M | 824K | 384K | 719K | 765K |
| Cash Flow | ||||||||||
| Operating Cash Flow | -662K | -7.53M | -22.9M | -24.6M | -32.1M | -8.73M | -21.8M | -19.0M | -22.7M | -16.3M |
| Capital Expenditure | 2.20K | 34.9K | 74.0K | 202K | 57.0K | 279K | 50.0K | 85.0K | 48.0K | 98.7K |
| Free Cash Flow | -664K | -7.56M | -23.0M | -24.8M | -32.1M | -9.01M | -21.8M | -19.1M | -22.8M | -16.4M |
| Ratios | ||||||||||
| ROE | - | -20.4% | -61.1% | -42.6% | -58.6% | -195.4% | -59.1% | -42.3% | -78.3% | -36.9% |
| ROA | -31.6% | -19.7% | -46.1% | -34.8% | -45.6% | -79.6% | -26.4% | -31.5% | -70.2% | -34.8% |
| Net Profit Margin | - | - | - | - | - | -396.1% | -37.0% | -19.6% | -17,229.2% | - |
| Debt to Equity | - | 0.00x | 0.23x | 0.14x | 0.16x | 0.32x | 0.04x | 0.02x | 0.03x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Equillium Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | USD 9.13M | 0.26 | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | USD 9.88M | 0.57 | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Equillium Inc
- Insiders 16.00%
- Institutions 67.52%
- Public & others 16.49%
- Shares outstanding 78.4M
- Free float 47.9M
Top funds holding EQ.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| abrdn Life Sciences Investors | 4.46M | 5.69% | +20.22% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 1.40M | 1.79% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 235K | 0.30% | +45.00% | Sep 2026 |
| iShares Micro-Cap ETF | 140K | 0.18% | 0.00% | Oct 2026 |
| Avantis US Small Cap Equity ETF | 75.4K | 0.10% | 0.00% | Oct 2026 |
| Fidelity Total Market Index | 56.3K | 0.07% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 51.6K | 0.07% | 0.00% | Sep 2026 |
| Invesco NASDAQ Future Gen 200 ETF | 51.6K | 0.07% | +1.92% | Oct 2026 |
| Fidelity Nasdaq Composite Index | 27.3K | 0.03% | -25.69% | Aug 2026 |
| China Universal Gbl YLBJ QDII CNH | 25.0K | 0.03% | 0.00% | Jun 2026 |
| Vanguard Balanced Index Inv | 25.0K | 0.03% | 0.00% | Sep 2026 |
| Vanguard MStar Inst Ttl StkMktIdxInstlPl | 22.5K | 0.03% | 0.00% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 20.0K | 0.03% | +244.04% | Sep 2026 |
| 1290 VT Micro Cap K | 9.86K | 0.01% | 0.00% | Sep 2026 |
| Victory Extended Market Index | 5.76K | 0.01% | +3.56% | Sep 2026 |
| JHVIT Total Stock Market Index I | 1.16K | 0.00% | 0.00% | Aug 2026 |
Top institutions holding EQ.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Jupiter Topco LLC | 6.49M | 8.29% | 0.00% | Jun 2026 |
| Decheng Capital LLC | 4.45M | 5.68% | 0.00% | Jun 2026 |
| Affinity Asset Advisors, LLC | 4.10M | 5.23% | +234.34% | Jun 2026 |
| ADAR1 Capital Management LLC | 3.76M | 4.80% | +0.86% | Jun 2026 |
| Aberdeen Group PLC | 3.63M | 4.63% | +8.32% | Jun 2026 |
| Woodline Partners LP | 3.50M | 4.47% | 0.00% | Jun 2026 |
| RA Capital Management, LLC | 3.10M | 3.95% | 0.00% | Jun 2026 |
| StemPoint Capital LP | 2.02M | 2.57% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.82M | 2.33% | +2.15% | Jun 2026 |
| Eversept Partners, LP | 1.52M | 1.94% | +1.46% | Jun 2026 |
| Adage Capital Partners Gp LLC | 1.39M | 1.77% | -73.91% | Jun 2026 |
| Renaissance Technologies Corp | 638K | 0.81% | -2.94% | Jun 2026 |
| Exome Asset Management LLC | 553K | 0.71% | 0.00% | Jun 2026 |
| DG Capital Management, LLC | 463K | 0.59% | 0.00% | Jun 2026 |
| Diadema Partners LP | 400K | 0.51% | -7.74% | Jun 2026 |
| Geode Capital Management, LLC | 381K | 0.49% | +0.62% | Jun 2026 |
| Balyasny Asset Management LLC | 344K | 0.44% | -78.98% | Jun 2026 |
| Tudor Investment Corp Et AL | 320K | 0.41% | +1,492.54% | Jun 2026 |
| Ikarian Capital, LLC | 304K | 0.39% | 0.00% | Jun 2026 |
| BlackRock Inc | 285K | 0.36% | +123.23% | Jun 2026 |
Equillium Inc company profile
- Company name
- Equillium Inc
- Ticker
- EQ.US
- Exchange
- USA Stocks
- Listed since
- Oct 11, 2018
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 14
- Fiscal year end
- December
- Address
- 2223 Avenida De La Playa, La Jolla, CA, United States, 92037
- Phone
- 858 240 1200
- Website
- equilliumbio.com
About Equillium Inc
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Equillium Inc management
6- Mr. Bruce SteelCo-Founder, CEO & Director · born 1966
- Dr. Stephen Connelly Ph.D.Chief Scientific Officer & President · born 1981
- Ms. Christine Zedelmayer M.B.A., P.M.P.Senior VP & COO · born 1970
- Ms. Penny Tom CPASenior VP of Finance & Principal Accounting Officer
- Mr. Michael MooreVice President of Investor Relations & Corporate Communications
- Dr. Lisette AcevedoVice President of Clinical Development